Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. IMDX, RNAC, DTIL, MIST, and SLGLShould you buy Nabriva Therapeutics stock or one of its competitors? MarketBeat compares Nabriva Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nabriva Therapeutics include Oncocyte (IMDX), Cartesian Therapeutics (RNAC), Precision BioSciences (DTIL), Milestone Pharmaceuticals (MIST), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. NBRV vs. IMDXNBRV vs. RNACNBRV vs. DTILNBRV vs. MISTNBRV vs. SLGLHow does Nabriva Therapeutics compare to Oncocyte?Nabriva Therapeutics (NASDAQ:NBRV) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Do analysts prefer NBRV or IMDX? Oncocyte has a consensus price target of $12.00, indicating a potential upside of 97.04%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts clearly believe Oncocyte is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncocyte 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation and earnings, NBRV or IMDX? Oncocyte has lower revenue, but higher earnings than Nabriva Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/AOncocyte$4.05M48.55-$50.22M-$1.48N/A Which has more risk & volatility, NBRV or IMDX? Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Is NBRV or IMDX more profitable? Nabriva Therapeutics has a net margin of -148.11% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Oncocyte -2,454.64%N/A -96.96% Does the media refer more to NBRV or IMDX? In the previous week, Nabriva Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Overall Sentiment Nabriva Therapeutics Neutral Oncocyte Neutral Do insiders & institutionals believe in NBRV or IMDX? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 2.1% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryOncocyte beats Nabriva Therapeutics on 10 of the 13 factors compared between the two stocks.How does Nabriva Therapeutics compare to Cartesian Therapeutics?Nabriva Therapeutics (NASDAQ:NBRV) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Which has preferable earnings and valuation, NBRV or RNAC? Nabriva Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ACartesian Therapeutics$2.80M70.83-$130.30M-$5.90N/A Do analysts rate NBRV or RNAC? Cartesian Therapeutics has a consensus price target of $33.00, indicating a potential upside of 388.89%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cartesian Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is NBRV or RNAC more profitable? Nabriva Therapeutics has a net margin of -148.11% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Cartesian Therapeutics -8,550.65%N/A -28.25% Does the media prefer NBRV or RNAC? In the previous week, Cartesian Therapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Cartesian Therapeutics and 0 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score. Company Overall Sentiment Nabriva Therapeutics Neutral Cartesian Therapeutics Neutral Do institutionals & insiders believe in NBRV or RNAC? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, NBRV or RNAC? Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. SummaryCartesian Therapeutics beats Nabriva Therapeutics on 9 of the 14 factors compared between the two stocks.How does Nabriva Therapeutics compare to Precision BioSciences?Nabriva Therapeutics (NASDAQ:NBRV) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Which has more risk & volatility, NBRV or DTIL? Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Do analysts rate NBRV or DTIL? Precision BioSciences has a consensus price target of $24.50, suggesting a potential upside of 238.87%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders believe in NBRV or DTIL? 0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor NBRV or DTIL? In the previous week, Precision BioSciences had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Precision BioSciences and 0 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.05 indicating that Nabriva Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Nabriva Therapeutics Neutral Precision BioSciences Neutral Is NBRV or DTIL more profitable? Precision BioSciences has a net margin of -96.73% compared to Nabriva Therapeutics' net margin of -148.11%. Precision BioSciences' return on equity of -85.37% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Precision BioSciences -96.73%-85.37%-37.34% Which has higher earnings and valuation, NBRV or DTIL? Precision BioSciences has lower revenue, but higher earnings than Nabriva Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/APrecision BioSciences$34.26M5.44-$45.72M-$3.67N/A SummaryPrecision BioSciences beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.How does Nabriva Therapeutics compare to Milestone Pharmaceuticals?Milestone Pharmaceuticals (NASDAQ:MIST) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations. Which has more volatility & risk, MIST or NBRV? Milestone Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Does the media prefer MIST or NBRV? In the previous week, Milestone Pharmaceuticals had 7 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 7 mentions for Milestone Pharmaceuticals and 0 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 beat Milestone Pharmaceuticals' score of -0.50 indicating that Nabriva Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Milestone Pharmaceuticals Negative Nabriva Therapeutics Neutral Is MIST or NBRV more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Milestone Pharmaceuticals' return on equity of -339.33% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -339.33% -61.79% Nabriva Therapeutics -148.11%-365.53%-135.81% Which has better earnings & valuation, MIST or NBRV? Nabriva Therapeutics has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1.55M113.25-$63.06M-$0.68N/ANabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do analysts rate MIST or NBRV? Milestone Pharmaceuticals presently has a consensus price target of $7.25, indicating a potential upside of 414.18%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in MIST or NBRV? 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryMilestone Pharmaceuticals beats Nabriva Therapeutics on 11 of the 16 factors compared between the two stocks.How does Nabriva Therapeutics compare to Sol-Gel Technologies?Sol-Gel Technologies (NASDAQ:SLGL) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Do institutionals and insiders have more ownership in SLGL or NBRV? 26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, SLGL or NBRV? Sol-Gel Technologies has higher earnings, but lower revenue than Nabriva Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$19.39M11.12-$6.13M-$2.23N/ANabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do analysts prefer SLGL or NBRV? Sol-Gel Technologies presently has a consensus price target of $110.00, indicating a potential upside of 43.36%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Sol-Gel Technologies is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SLGL or NBRV? In the previous week, Sol-Gel Technologies had 12 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 12 mentions for Sol-Gel Technologies and 0 mentions for Nabriva Therapeutics. Sol-Gel Technologies' average media sentiment score of 1.01 beat Nabriva Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Overall Sentiment Sol-Gel Technologies Positive Nabriva Therapeutics Neutral Which has more risk and volatility, SLGL or NBRV? Sol-Gel Technologies has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Is SLGL or NBRV more profitable? Sol-Gel Technologies has a net margin of -31.60% compared to Nabriva Therapeutics' net margin of -148.11%. Sol-Gel Technologies' return on equity of -24.29% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-31.60% -24.29% -18.73% Nabriva Therapeutics -148.11%-365.53%-135.81% SummarySol-Gel Technologies beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition ExportMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$927.43M$6.45B$12.34BDividend YieldN/A4.84%2.76%5.28%P/E Ratio0.001.4621.2225.65Price / SalesN/A119.63553.9286.28Price / CashN/A20.0743.4956.67Price / BookN/A7.5910.377.14Net Income-$57.19M-$3.64M$3.57B$335.98M Nabriva Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59MN/A70IMDXOncocyte2.3042 of 5 stars$6.19+11.3%$12.00+93.9%N/A$179.53M$1.95MN/A120RNACCartesian Therapeutics2.6296 of 5 stars$6.52+7.1%$33.00+406.1%-26.3%$178.93M$2.80MN/A64DTILPrecision BioSciences1.9045 of 5 stars$7.18+4.1%$24.50+241.2%+57.9%$178.04M$34.26MN/A200MISTMilestone Pharmaceuticals2.548 of 5 stars$1.50+4.9%$7.25+383.3%-8.4%$178.03M$1.55MN/A30Gap Up Related Companies and Tools Related Companies IMDX Alternatives RNAC Alternatives DTIL Alternatives MIST Alternatives SLGL Alternatives TLSA Alternatives ORMP Alternatives BDTX Alternatives IFRX Alternatives TNYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
